Immedica Ab Patent-Cliff Exposure & CMS Drug Spending Portfolio

Immedica Ab (US): 2 reconciled FDA prescription therapies, $24.1M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2042-01-01
2024 CMS Total Public Spend$24.1M
2024 Medicare Part D Spend$2.0M
2024 Medicaid Spend$22.2M
California HCAI SB 17 Filings1 WAC filings (max 19.9% 2-yr change)